



Personalized Treatment in Cancer Research

Guest Editors:

Dr. Sarah Allegra

Department of Clinical and
Biological Sciences, University of
Turin, 10124 Torino, Italy

Dr. Silvia De Francia

Department of Biological and
Clinical Sciences, University of
Turin, S. Luigi Gonzaga Hospital,
10043 Orbassano, Italy

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editors

Dear Colleagues,

In oncology, personalized medicine is an emerging approach for tumour therapy that takes into consideration the interindividual variability in treatment outcome and toxicity of each cancer patient. The personalization has the potential to tailor therapy towards the pharmacogenetics and pharmacokinetics drivers of treatment outcome and thus on patient quality of life. Furthermore, this could be the key to avoid suboptimal drug dosing or adverse events, taking into account the genetic variability of each person, their sex and their age. The Special Issue, “Personalized Treatment in Cancer Research”, will focus on tailored treatment in cancer research, including clinical, preclinical, pharmacological and translational studies.

Dr. Sarah Allegra

Dr. Silvia De Francia

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)